The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.

The U.S. Food and Drug Administration approved Karyopharm Therapeutics Inc.’s Xpovio (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Genentech’s influenza treatment Xofluza (baloxavir marboxil) was granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the regulatory agency.

To support the long-term goals of Novartis, the Swiss pharma giant is initiating a share-buyback program of up to $2.5 billion that is expected to be carried out over the next few months.

Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.

Amgen and AstraZeneca announced that their Phase III NAVIGATOR trial of the potential first-in-class human monoclonal antibody tezepelumab hit the primary endpoint in severe asthma.

Gilead Sciences Inc. and Immunomedics announced that the companies entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.

Sociétés des Produits Nestlé, a part of Nestlé Health Science, acquired the outstanding shares of California-based Aimmune for $2.6 billion in cash following years of increasing its financial position in the food allergy-focused company.

Dermavant Sciences announced positive data from two Phase III clinical trials evaluating tapinarof cream 1% in adults with plaque psoriasis.

AstraZeneca reported successful results from the company’s Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end-stage kidney disease.